Target intelligence / Profile preview

GRID1 antisense RNA 2 (GRID1-AS2)

Target
GRID1-AS2
Molecular classification
Long non-coding RNA, Antisense RNA, Non-coding RNA
01

Overview

GRID1 antisense RNA 2 (GRID1-AS2) is a long non-coding RNA transcribed antisense to the GRID1 locus, likely functioning as a regulator of the GRID1 gene or neighboring genes. Like other antisense lncRNAs, it may exert its function via RNA-DNA, RNA-RNA, or RNA-protein interactions, often influencing chromatin structure or mRNA stability. There is no current evidence that it is a therapeutic target or directly associated with disease, although antisense lncRNAs as a class have roles in gene regulation and can impact cellular processes important in health and disease[1][3][5].\n\nIn summary, GRID1-AS2 is a gene regulatory lncRNA, not a standard therapeutic target, and currently lacks characterized disease associations or drug interactions.

02

Mechanism of action

Not established for any drug (as no direct drug interactions). Antisense lncRNAs in general can modulate gene expression by base-pairing with sense mRNA, affecting stability, translation, and/or splicing

03

Biological functions

Regulation of gene expression (through RNA-RNA or RNA-protein interactions)Possible epigenetic modification and chromatin remodeling (by analogy to other antisense lncRNAs)
04

Disease associations

Other

Beyond the preview

Go deeper on GRID1 antisense RNA 2 (GRID1-AS2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GRID1 antisense RNA 2 (GRID1-AS2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call